Ciphergen Names Executive Vice President, Pharmaceutical Corporate Development
March 14 2005 - 9:02AM
PR Newswire (US)
Ciphergen Names Executive Vice President, Pharmaceutical Corporate
Development FREMONT, Calif., March 14 /PRNewswire-FirstCall/ --
Ciphergen Biosystems, Inc. (NASDAQ:CIPH) announced today that James
P. Merryweather, Ph.D. has joined Ciphergen as Executive Vice
President, Pharmaceutical Corporate Development. In his new
position, Dr. Merryweather will manage Ciphergen's relationships
with key pharmaceutical clients based on use of Ciphergen's
ProteinChip technology and collaborative services provided through
Ciphergen's Biomarker Discovery Center(R) laboratory in Malvern,
Pennsylvania and manage pharmaceutical biomarker collaborations.
"We are pleased that Jim is joining Ciphergen to provide critical
pharmaceutical drug discovery and development expertise," stated
William E. Rich, Ciphergen's President and CEO. "He will apply
seasoned management skills to our efforts to adapt our technology
and collaborations more broadly within the pharmaceutical industry,
which is increasingly incorporating biomarkers in their drug
discovery and development programs." Dr. Merryweather has spent
over 20 years in the biotechnology industry in senior positions in
Research and Development, Program Management and Business
Development. Prior to joining Ciphergen, he spent five years at
Incyte Corporation, most recently as Executive Vice President of
Business Development & Commercial Operations. Prior to joining
Incyte, Dr. Merryweather was at Millennium Pharmaceuticals as Vice
President, Program Management. Prior to joining Millennium, he
spent 15 years at Chiron Corporation in a variety of roles ranging
from Senior Scientist to Director of Project Management. Dr.
Merryweather graduated with a B.S. degree in Chemistry from
Northern Illinois University and a Ph.D. in Biochemistry from
Washington State University. About Ciphergen Ciphergen's Biosystems
Division develops, manufactures and markets a family of
ProteinChip(R) Systems and services for clinical, research, and
process proteomics applications. ProteinChip Systems enable protein
discovery, characterization, identification and assay development
to provide researchers with predictive, multi-marker assay
capabilities and a better understanding of biological function at
the protein level. Ciphergen's Diagnostics Division is dedicated to
the discovery of protein biomarkers and panels of biomarkers and
their development into protein molecular diagnostic tests that
improve patient care; and to providing collaborative R&D
services through its Biomarker Discovery Center(R) laboratories for
biomarker discovery for new diagnostic tests as well as
pharmacoproteomic services for improved drug toxicology, efficacy
and theranostic assays. Additional information about Ciphergen can
be found at http://www.ciphergen.com/. Safe Harbor Statement Note
Regarding Forward-Looking Statements: For purposes of the Private
Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
forward-looking statements include statements regarding the use of
ProteinChip technology to discover useful protein biomarkers,
develop and commercialize clinical diagnostics that improve patient
care, the ability to provide services that lead to improved
toxicology assays and diagnostic assays, and statements regarding
our Diagnostics Division. Actual results may differ materially from
those projected in such forward-looking statements due to various
factors, including the ProteinChip technology's ability to validate
and/or develop protein biomarkers as diagnostic or toxicology
assays, and the Company's ability to successfully commercialize
such tests. Investors should consult Ciphergen's filings with the
Securities and Exchange Commission, including its Form 10-Q dated
November 9, 2004, for further information regarding these and the
other risks of the Company's business. NOTE: Ciphergen,
ProteinChip, and Biomarker Discovery Center are registered
trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen
Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of
Ciphergen Biosystems, Inc., +1-510-505 2297 Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024